New drug shows promise for painful skin condition
NCT ID NCT04856930
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 19 times
Summary
This study tested a drug called imsidolimab in 149 people with hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The goal was to see if the drug reduces the number of abscesses and inflamed nodules compared to a placebo over 16 weeks. The trial is now complete, and results will help determine if this treatment can ease symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 10-101
Fort Gratiot, Michigan, 48059, United States
-
Site 10-102
Sacramento, California, 95817, United States
-
Site 10-103
Portsmouth, New Hampshire, 03801, United States
-
Site 10-104
Fountain Valley, California, 92708, United States
-
Site 10-105
Norfolk, Virginia, 23502, United States
-
Site 10-106
Spokane, Washington, 99202, United States
-
Site 10-107
Largo, Florida, 33770, United States
-
Site 10-108
Birmingham, Alabama, 35224, United States
-
Site 10-109
Coral Gables, Florida, 33134, United States
-
Site 10-110
Sandy Springs, Georgia, 30328, United States
-
Site 10-111
Tampa, Florida, 33607, United States
-
Site 10-112
Pflugerville, Texas, 78660, United States
-
Site 10-113
Greenville, South Carolina, 29615, United States
-
Site 10-115
Warwick, Rhode Island, 02886, United States
-
Site 10-117
San Antonio, Texas, 78213, United States
-
Site 10-118
Houston, Texas, 77056, United States
-
Site 10-119
Northridge, California, 91324, United States
-
Site 11-101
Saint-Jérôme, Quebec, J7Z 7E2, Canada
-
Site 11-102
Markham, Ontario, L3P 1X3, Canada
-
Site 11-103
Cobourg, Ontario, K9A 0Z4, Canada
-
Site 11-105
Québec, Quebec, G1N 4V3, Canada
-
Site 11-106
Calgary, Alberta, T2J7E1, Canada
-
Site 30-103
Ossy, Silesian Voivodeship, 42-624, Poland
-
Site 30-104
Rzeszów, Podkarpackie Voivodeship, 35-055, Poland
-
Site 30-106
Olsztyn, 10-229, Poland
-
Site 30-107
Krakow, Malopolska, 30-074, Poland
-
Site 30-108
Katowice, Silesian Voivodeship, 40-611, Poland
-
Site 30-109
Lodz, 90-265, Poland
-
Site 59-102
Tbilisi, 112, Georgia
-
Site 59-103
Tbilisi, 160, Georgia
-
Site 59-104
Tbilisi, 159, Georgia
-
Site 59-105
Tbilisi, 160, Georgia
-
Site 59-106
Batumi, 6000, Georgia
-
Site 59-107
Tbilisi, 162, Georgia
Conditions
Explore the condition pages connected to this study.